Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | TNNI3 | P19429 | 2/20 | 0.65 |
| ▸ | TNNT2 | P45379 | 2/20 | 0.65 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598358 | 0.98 | CTSB (0.97) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL6712876 | 0.87 | CTSB (0.76) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL3620838 | 0.87 | CTSB (0.76) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL4871537 | 0.86 | AR (0.74) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL4871412 | 0.86 | CTSB (1.00) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL22858551 | 0.86 | CTSB (0.75) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL29577374 | 0.86 | CTSB (0.75) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL2711827 | 0.86 | CTSB (0.75) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL4880599 | 0.83 | CTSB (0.70) | CTSBARMAPTHTTSMN1; SMN2 | |
| SCHEMBL6712806 | 0.82 | CTSB (0.69) | CTSBARMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | claimed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | claimed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | claimed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | claimed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| EP-2010494-B1 | SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES | OREAL (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-8012220-B2 | Specific monocationic monochromophoric compounds of hydrazone type comprising a 2-, 4-pyridinium or 2-, 4-quinolinium unit, synthesis thereof, dye compositions containing them, and method for dyeing keratin fibres | L'OREAL S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-8012220-B2 | Specific monocationic monochromophoric compounds of hydrazone type comprising a 2-, 4-pyridinium or 2-, 4-quinolinium unit, synthesis thereof, dye compositions containing them, and method for dyeing keratin fibres | L'OREAL S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090300856-A1 | SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES | L'OREAL S.A. (FR) | 2009-12-10 | — | — | US | disclosed |
| US-20090300856-A1 | SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES | L'OREAL S.A. (FR) | 2009-12-10 | — | — | US | disclosed |
| US-20090042857-A1 | Novel Pharmaceutical | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| WO-2007092391-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090300856-A1 | SPECIFIC MONOCATIONIC MONOCHROMOPHORIC COMPOUNDS OF HYDRAZONE TYPE COMPRISING A 2-, 4-PYRIDINIUM OR 2-, 4-QUINOLINIUM UNIT, SYNTHESIS THEREOF, DYE COMPOSITIONS CONTAINING THEM, AND METHOD FOR DYEING KERATIN FIBRES | KRT18, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-5 | CTSB 3617/4885AR 1675/4885MAPT 2118/4885 |
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | CTSB 4422/4885AR 1/4885MAPT 4707/4885 |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | CTSB 2931/4885AR 2/4885MAPT 3702/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | CTSB 2995/4885AR 2/4885MAPT 3809/4885 |
| US-20090042857-A1 | Novel Pharmaceutical | AR, NR5A1, NR5A2 | CTSB 3158/4885AR 1/4885MAPT 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.